The Eyquem lab is a highly collaborative group passionate about using synthetic immunology to advance adoptive cell therapies.
Our Research
Our laboratory is aimed at understanding the current limitations of CAR T cell therapy using innovative tumor models and functional genomics and overcoming these challenges by reprogramming T cells with the use of genome editing and synthetic receptors.
Our Partners
Our People
The Eyquem lab is a highly collaborative group passionate about using synthetic immunology to advance adoptive cell therapies.
News
Media highlights of Eyquem Lab's research.
Stay Updated
Keep up-to-date with the latest research from the Eyquem lab.
A new preprint from the lab in collaboration with @doudna_lab, @HowardYChang, @carlhjune and ...@j_eyquem to investigate and mitigate aneuploidy in edited human T cells: https://www.biorxiv.org/content/10.1101/2023.03.22.533709v1. Kudos to @connortsuchida and @BrandesNadav for driving this project. Tweetorial 👇 https://twitter.com/connortsuchida/status/1639065941622546432
Tour de force from @Majzner_Lab ! Such an elegant spin on CAR design, tons of new insight in CAR ...signaling and new ways to reprogram T cells. Can’t wait to play with these new tools. Bravo!
Recent Lab News
June 2021
Joe Muldoon was selected for the Cancer Research Institute Irvington Postdoctoral Fellowship
December 2020
Vincent Allain was selected for the ARC foundation International Mobility Award
August 2020
William Nyberg was selected for the Swedish Society for Medical Research fellowship
December 2019
Alexis Talbot was selected for the Fondation de France Fellowship